TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02087826

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mixed Meal Tolerance Test
Description: The meal will provide a standard amount of total calories, protein, fat, and carbohydrate to each participant at both study visits. Pre-packaged and prepared food, weighed to the nearest gram, will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be administered during this study. This medication is safely prescribed at a maximum dose of 1000 mg twice daily for the treatment or prevention of type 2 diabetes, as well as for other metabolic conditions. To minimize potential side effects of metformin (e.g., GI upset), participants will take ½ the maximum dose of this medication (500 mg twice daily) and for only 5 days. Participants will be informed of the potential side effects of metformin. They will be asked to contact study staff and discontinue the medication if symptoms are very uncomfortable.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin will be administered during this study. This medication is safely prescribed at a maximum dose of 1000 mg twice daily for the treatment or prevention of type 2 diabetes, as well as for other metabolic conditions. To minimize potential side effects of metformin (e.g., GI upset), participants will take ½ the maximum dose of this medication (500 mg twice daily) and for only 5 days. Participants will be informed of the potential side effects of metformin. They will be asked to contact study staff and discontinue the medication if symptoms are very uncomfortable.
Study: NCT03889197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium supplementation guided by urine sodium concentration algorithm
Description: 4 mEq/kg/d sodium added the first time urine \[Na\] below threshold; for each subsequent time urine \[Na\] below threshold, add additional 2 mEq/kg/d.
Study: NCT04556773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Capivasertib: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant: administered as an IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: administered orally
Study: NCT02422030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor Tab. 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor Tab. 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilipix 135mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilipix 135mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilipix 135mg
Study: NCT03393312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Electric current

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Electric current
Study: NCT03184376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic oligofructose
Description: Powder format

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo maltodextrin
Description: Powder format
Study: NCT04925531

Intervention type: DRUG
Intervention: Antibiotics
Description: to examine if either the utility of antibiotics administered for 3 days or 5 days make a difference in the clinical outcomes after facial fractures in trauma patients.
Study: NCT02422030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilipix 135mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilipix 135mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilipix 135mg
Study: NCT02367313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vapendavir
Description: Vapendavir 264 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vapendavir
Description: Vapendavir 528 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study: NCT03639480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
Description: Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10mg+Valsartan 160mg
Description: Amlodipine 10mg+Valsartan 160mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160mg+Atorvastatin 40mg
Description: Valsartan 160mg+Atorvastatin 40mg
Study: NCT03969342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point of care ultrasound training
Description: Five-day in-person training on point of care ultrasound using portable ultrasound devices followed by remote monitoring of practice scanning
Study: NCT00298038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT05435599

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum regucalcin level
Description: During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum regucalcin level
Description: During routine outpatient controls, serum regucalcin level will be measured from the rest of the blood taken for examinations.
Study: NCT00788866

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice
Description: 8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
Study: NCT04231435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral
Study: NCT00909259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phrenic stimulation device
Description: In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation. A second lead may also be placed for sensing purposes. The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment. Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment. In Stage 2, a stimulation device and lead will be permanently implanted.
Study: NCT05506020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indocyanine green (ICG) fluorescence cholangiography
Description: indocyanine green (ICG) fluorescence cholangiography during operation
Study: NCT00503685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: 10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: 10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
Study: NCT00696423

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix™
Description: Intramuscular injection, one dose
Study: NCT01383707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: Participants will receive 5-FU 400 mg per meter-squared (mg/m\^2) IV dose on Day 1 of each 2 weeks' cycle followed by 2400 mg/m\^2, continuous infusion over 46 hours up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive 5 mg/kg bevacizumab IV dose on Day 1 of each 2 weeks' cycle up to Cycle 5 and thereafter cycles 7 to 12; followed by maintenance therapy of 5 mg/kg IV every 2 weeks up to 52 weeks (26 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinic acid
Description: Participants will receive levofolinic acid 200 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
Study: NCT04057742

Intervention type: DIAGNOSTIC_TEST
Intervention: AlloSure ddcfDNA assay
Description: 2.5 mL collection for Donor Derived Cell Free DNA at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C

Intervention type: DIAGNOSTIC_TEST
Intervention: AlloSure ddcfDNA assay
Description: 2.5 mL collection for Donor Derived Cell Free DNA at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C

Intervention type: DIAGNOSTIC_TEST
Intervention: AlloSure ddcfDNA assay
Description: 2.5 mL collection for Donor Derived Cell Free DNA at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C

Intervention type: DIAGNOSTIC_TEST
Intervention: AlloMap assay
Description: 10 mL collection PAXgene blood sample at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C

Intervention type: DIAGNOSTIC_TEST
Intervention: AlloMap assay
Description: 10 mL collection PAXgene blood sample at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C

Intervention type: DIAGNOSTIC_TEST
Intervention: AlloMap assay
Description: 10 mL collection PAXgene blood sample at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory Cytokines
Description: 10 mL collection at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A
Study: NCT00503685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: 10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
Study: NCT04057742

Intervention type: DIAGNOSTIC_TEST
Intervention: Immune Cell Phenotypes
Description: Collection of up to 1 cup of urine for per participant each study visit

Intervention type: DIAGNOSTIC_TEST
Intervention: Immune Cell Phenotypes
Description: Collection of up to 1 cup of urine for per participant each study visit

Intervention type: DIAGNOSTIC_TEST
Intervention: Immune Cell Phenotypes
Description: Collection of up to 1 cup of urine for per participant each study visit
Study: NCT00503685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
Study: NCT00927927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0142-0002
Description: Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
Study: NCT00820339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Hepatic Vascular Exclusion
Description: Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pringle's Maneuver
Description: Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
Study: NCT02541266

Intervention type: OTHER
Intervention: Questionnaire
Description: A short questionnaire (9 questions) will be given to the participants to complete.

Intervention type: OTHER
Intervention: Questionnaire
Description: A short questionnaire (9 questions) will be given to the participants to complete.

Intervention type: OTHER
Intervention: Questionnaire
Description: A short questionnaire (9 questions) will be given to the participants to complete.
Study: NCT01578551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days~Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days~Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000 mg twice daily with food.
Study: NCT02306174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding
Description: The group sessions consists of 20 classes, each lasting approximately 90 minutes and may consist of some or all of the following:~* A group agreement and a confidentiality contract~* Homework assignments~* Viewing informational videos about hoarding~* Behavioral experiments including sorting and discarding exercises~* Non-acquisition exposures~This course is based on the Manual Cognitive Rehabilitation and Exposure/Sorting Therapy for Compulsive Hoarding (Ayers et al., 2014).
Study: NCT03259763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumen-apposing metal stent
Description: In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-expandable metal stent
Description: In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
Study: NCT03311217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy retail strategies
Study: NCT01251874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Given FLT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT00485108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone 1%
Description: eye drop once in each eye treated, 4 times / day for 5 days post-laser

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac 0.5%
Description: eye drop once in each eye treated, 4 times / day for 5 days post-laser

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Tears (Methyl cellulose drops)
Description: eye drop once in each eye treated, 4 times / day for 5 days post-laser
Study: NCT01181895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: Vilanterol inhalation powder inhaled orally once daily for 12 weeks
Study: NCT01251874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO